Pulmonary arterial hypertension (PAH)
INSMInsmed IncorporatedCatalyst overview
Research summary
This catalyst tracks a Phase 3 initiation for TPIP (Treprostinil Palmitil Inhalation Powder) in Pulmonary arterial hypertension (PAH). The expected timing is based on the latest available company guidance and may change.
10/26/23- Reported interim data. 6/10/25- Reported new data. Ph3 planned in early 2026. 9/22/25- Presentation at ERS'25 on Sep 30, 2025. 01/28/26:- PVRI 2026 will feature TPIP Phase 2b PAH data, FRI analysis, and PALM-PAH Phase 3 design January 31, 2026. 05/04/26:- TPIP population pharmacokinetics analysis from Phase 1-2 studies will be presented May 18. 07/16/26:- Reported positive 12-month OLE data. Phase 3 PALM-PAH study recently initiated.
Verification
Confirm timing and program details against the company announcement or filing.